Summit Therapeutics
SMMT
11 hedge funds and large institutions have $32.6M invested in Summit Therapeutics in 2015 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 1 closing their positions.
10% more capital invested
Capital invested by funds: $29.5M → $32.6M (+$3.05M)
0% more funds holding
Funds holding: 11 → 11 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$108K |
| 2 |
Axa
Paris,
France
|
+$10.4K |
| 3 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$1.04K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$104K |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$31K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$10.6K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$9K |
| 5 |
Morgan Stanley
New York
|
-$21 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LPU
1
Lansdowne Partners (UK)
London,
United Kingdom
| $10.7M | – | – | – |
|
|
2
Point72 Asset Management
Stamford,
Connecticut
| $10.7M | +$108K | +10,361 | +1% |
|
|
3
Axa
Paris,
France
| $4.34M | +$10.4K | +1,000 | +0.3% |
|
|
SFM
4
Sphera Funds Management
Tel Aviv,
Israel
| $2.32M | -$31K | -2,980 | -1% |
|
5
First Eagle Investment Management
New York
| $2.01M | – | – | – |
|
|
GPCM
6
Granite Point Capital Management
Boston,
Massachusetts
| $1.35M | -$104K | -10,000 | -8% |
|
|
EAM
7
EverPoint Asset Management
Stamford,
Connecticut
| $1.15M | – | – | – |
|
8
Wells Fargo
San Francisco,
California
| $29K | – | – | – |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $2K | -$10.6K | -1,023 | -83% |
|
|
LTFS
10
Ladenburg Thalmann Financial Services
Miami,
Florida
| $1K | +$1.04K | +100 | New |
|
|
11
UBS Group
Zurich,
Switzerland
| – | -$9K | -880 | Closed |
|
|
12
Morgan Stanley
New York
| – | -$21 | -2 | -22% |
|
SMMT Hedge Fund Activity: Q4 2015 in Review
11 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q4 2015, worth a combined $32.6M — up 10% from $29.5M a quarter earlier.
Fund positioning in SMMT was balanced in Q4 2015: 1 fund opened new positions, 1 closed out, 2 added to existing stakes and 4 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $108K. The largest seller was Granite Point Capital Management, cutting an estimated $104K.
- 11 institutional investors held Summit Therapeutics (SMMT) as of Q4 2015, unchanged from Q3 2015.
- Funds reported $32.6M of Summit Therapeutics stock for Q4 2015, up 10% quarter-over-quarter.
- 1 fund opened new Summit Therapeutics positions in Q4 2015 and 1 closed out, a net change of 0 holders.
- The largest Summit Therapeutics buyer in Q4 2015 was Point72 Asset Management, an estimated $108K added.
- The largest Summit Therapeutics seller in Q4 2015 was Granite Point Capital Management, an estimated $104K sold.
Based on aggregated 13F filings for Q4 2015.